Although several target therapies including imatinib, a BCR-ABL tyrosine kinase inhibitor, have revolutionized the CML therapy as a classic model for targeted therapy in other cancer types, their efficacies against CSCs have been challenged [7, 8]. The gene discussed is ABL1; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.